利用FVB/N-DR1转基因小鼠模型研究源自硕大利什曼原虫gp63的HLA-DR1限制性肽段的免疫原性
Immunogenicity of HLA-DR1 Restricted Peptides Derived from Leishmania major gp63 Using FVB/N-DR1 Transgenic Mouse Model.
作者信息
Rezvan H
机构信息
Dept. of Laboratory Science, School of Paraveterinary Sciences, Bu-Ali Sina University, Hamadan, Iran.
出版信息
Iran J Parasitol. 2013 Apr;8(2):273-9.
BACKGROUND
Leishmaniasis is a worldwide disease prevalent in tropical and sub-tropical countries. In the present study the immunogenicity of three human HLA-DR1 restricted peptides derived from L. major gp63 protein was evaluated using FVB/N-DR1 transgenic mouse model.
METHODS
The immunity generated by three MHC class II - restricted peptides with the sequence of AARLVRLAAAGAAVT (AAR), AAPLVRLAAAGAAVT (AAP) and SRYDQLVTRVVTHE (ASR) derived from L. major gp63 protein were predicted using a web-based software (SYFPEITHI) and tested in FVB/N-DR1 transgenic mice.
RESULTS
Immunization of FVB/N-DR1 transgenic mice with one of the three predicted peptides (AAR) resulted in high levels of Th1-type immune response as well as significant levels of IFN-γ detected by Proliferation assay and ELISA.
CONCLUSION
The results indicate a high level of immunogenicity for AAR, which can be a potent candidate for peptide vaccine in Leishmania infections.
背景
利什曼病是一种在热带和亚热带国家流行的全球性疾病。在本研究中，使用FVB/N-DR1转基因小鼠模型评估了源自硕大利什曼原虫gp63蛋白的三种人类HLA-DR1限制性肽的免疫原性。
方法
使用基于网络的软件（SYFPEITHI）预测源自硕大利什曼原虫gp63蛋白的三种MHC II类限制性肽（序列分别为AARLVRLAAAGAAVT（AAR）、AAPLVRLAAAGAAVT（AAP）和SRYDQLVTRVVTHE（ASR））产生的免疫反应，并在FVB/N-DR1转基因小鼠中进行测试。
结果
用三种预测肽之一（AAR）免疫FVB/N-DR1转基因小鼠，通过增殖试验和酶联免疫吸附测定法检测到高水平的Th1型免疫反应以及显著水平的干扰素-γ。
结论
结果表明AAR具有高度免疫原性，它可能是利什曼原虫感染肽疫苗的有力候选者。
Zotero 插件